The US Supreme Court will hear arguments on the legality of President Trump's tariffs, which were imposed under emergency economic powers and face challenges over the limits of executive authority.
Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
Core & Main reports strong Q2 results, but cuts full-year outlook due to higher costs and weaker residential demand.
The US Supreme Court will hear arguments on the legality of President Trump's tariffs, which were imposed under emergency economic powers and face challenges over the limits of executive authority.
Novartis to acquire US biotech Tourmaline Bio for $1.4B, bolstering its cardiovascular pipeline with a promising anti-inflammatory drug candidate.
Core & Main reports strong Q2 results, but cuts full-year outlook due to higher costs and weaker residential demand.